Sustained 3-year efficacy of pre- and coseasonal 5-grass-pollen sublingual immunotherapy tablets in patients with grass pollen–induced rhinoconjunctivitis
Authors:
- Alain DidierADAlain Didier
- Margitta WormMWMargitta Worm
- Friedrich HorakFHFriedrich Horak
- Gordon SussmanGSGordon Sussman
- Olivier de BeaumontOBOlivier de Beaumont
- Martine Le GallMGMartine Le Gall
- Michel MelacMMMichel Melac
- Hans-Jorgen MallingHMHans-Jorgen Malling
- 1 September 2011
- journal article
- research article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 128 (3) , 559-566
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- The average Adjusted Symptom Score, a new primary efficacy end‐point for specific allergen immunotherapy trialsClinical & Experimental Allergy, 2011
- Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT studyAllergy, 2008
- Allergic Rhinitis and its Impact on Asthma (ARIA) 2008*Allergy, 2008
- Sublingual grass allergen tablet immunotherapy provides sustained clinical benefit with progressive immunologic changes over 2 yearsJournal of Allergy and Clinical Immunology, 2008
- Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitisJournal of Allergy and Clinical Immunology, 2006
- Allergy Practice Worldwide: A Report by the World Allergy Organization Specialty and Training CouncilInternational Archives of Allergy and Immunology, 2006
- Prevalence and rate of diagnosis of allergic rhinitis in EuropeEuropean Respiratory Journal, 2004
- Consensus statement * on the treatment of allergic rhinitisAllergy, 2000
- National guidelines needed to manage rhinitis and prevent complicationsAnnals of Allergy, Asthma & Immunology, 1999
- Interpretation of rhinoconjunctivitis quality of life questionnaire dataJournal of Allergy and Clinical Immunology, 1996